The Nasal Drug Delivery Technology Market Report 2022-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Demand for Alternative Drug Delivery Methods Coupled with Advancements In Product Development Driving Market Growth
Some of the major forces propelling the nasal drug delivery technology market include surge in demand for better drug delivery methods, and advancements in product packing and development. Furthermore, rising prevalence of allergic rhinitis and increasing cases of asthma are expected to propel market growth. On the other hand, rise in adoption of generic nasal delivery drugs coupled with new launches are expected to further boost market growth. Developing a successful nasal drug product requires expertise in a variety of areas, including formulation develop...

The Rare Diseases Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Home-based Care Anticipated to Offer Lucrative Growth Prospects
There are unmet requirements for elderly, frail people with multiple diseases, but many support services today focus on patients with rare or ultra-rare diseases. In addition, there are numerous chronic conditions present in sizable patient communities, even in younger age groups. Expanding home-based healthcare services could therefore have positive effects on bigger patient populations and health systems.

Due to the high degrees of medical complexity, managing comorbidities and multi-morbidities is especially difficult. A patient with heart failure who also requires infusion therapy for cancer poses a problem with timing the a...

Summary

“Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies provides comprehensive information about the Alzheimer pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Alzheimer is a progressive neurologic disorder beginning with mild memory loss and possibly leading to loss of the ability to carry on a conversation and respond to the environment.

Scope

Extensive coverage of the Alzheimer under development

The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The report reviews the major players involved in the development of Alzheimer and list all their pipeline projects

The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

The report provides key clinical trial data of ongoi...

The HIV and HBV Therapies Market Report 2022-2032: This report will prove valuable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Factors Such as Rising Prevalence of HIV and HBV, High Investment in R&D, and Growing Government Support Are Driving the Market Growth
Some of the major forces propelling the global HIV and HBV therapies market include rising prevalence of HIV and HBV, high investment in R&D, and growing government support. Robust government support for HIV and HBV therapies research is one of the major factors that propel the market growth. There is a need for significant collaborations among the pharmaceutical industry, foundations, patient advocacy organizations, academic and public researchers and financing programs, regulatory researchers and reimbursement organizations to identify and develop ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA),...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Drugs In Development, 2022, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under de...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2022, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.

Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Drugs In Development, 2022, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development his...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), r...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and la...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease With Vaso-Occlusive Crisis - Drugs In Development, 2022, provides an overview of the Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology) pipeline landscape.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease With Vaso-Occlusive Crisis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Sickle Cell Disease With Vaso-Occlusive Crisis (Hematology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease - Drugs In Development, 2022, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Drugs In Development, 2022, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

Global Markets Direct's Pharmaceutical a...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Drugs In Development, 2022, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insomnia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and lates...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2022, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline landscape.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aplastic Anemia - Drugs In Development, 2022, provides an overview of the Aplastic Anemia (Hematological Disorders) pipeline landscape.

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders and serious infections. Treatment includes immunosuppressants and stem cell transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aplastic Anemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Aplastic Anemia (Hematological Disorders), co...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fanconi Anemia - Drugs In Development, 2022, provides an overview of the Fanconi Anemia (Hematological Disorders) pipeline landscape.

Fanconi anemia (fan-KO-nee uh-NEE-me-uh), or FA, is a rare, inherited blood disorder that leads to bone marrow failure. The disorder also is called Fanconi’s anemia. FA is a type of aplastic anemia. In aplastic anemia, the bone marrow stops making or doesn't make enough of all three types of blood cells. Low levels of the three types of blood cells can harm many of the body's organs, tissues, and systems. Treatment is recommended for significant cytopenias, such as hemoglobin less than 8 g/dL, platelets fewer than 500/μL.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fanconi Anemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Fanconi Anemia (Hematological Disorders), complete with analysis by ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Drugs In Development, 2022, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide cov...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malaria - Drugs In Development, 2022, provides an overview of the Malaria (Infectious Disease) pipeline landscape.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea and vomiting. Treatment includes anti-malarial medicines and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malaria - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Malaria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule ty...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2022, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and...